Working Paper Case Report Version 3 This version is not peer-reviewed

Anti-diarrheal Effects of Wood Creosote, Seirogan, in Japanese Patients: A Retrospective Study

Version 1 : Received: 4 October 2019 / Approved: 7 October 2019 / Online: 7 October 2019 (10:52:58 CEST)
Version 2 : Received: 15 October 2019 / Approved: 16 October 2019 / Online: 16 October 2019 (09:35:15 CEST)
Version 3 : Received: 4 November 2019 / Approved: 6 November 2019 / Online: 6 November 2019 (11:49:10 CET)

How to cite: Ito, M. Anti-diarrheal Effects of Wood Creosote, Seirogan, in Japanese Patients: A Retrospective Study. Preprints 2019, 2019100058 Ito, M. Anti-diarrheal Effects of Wood Creosote, Seirogan, in Japanese Patients: A Retrospective Study. Preprints 2019, 2019100058

Abstract

Seirogan, a wood creosote, is a nonprescription drug used to treat diarrhea. However, reports of its clinical use are rare. Here, we report on the efficacy of wood creosote (3 capsules daily) for the alleviation of diarrheal symptoms in 148 patients from 10 clinics in Japan. The wood creosote capsules were classified as remarkably effective (44 patients), effective (71 patients), and partially effective (13 patients) based on the degree of alleviation of diarrheal symptoms that were induced by a variety of causes. The antidiarrheal efficacy of the capsules did not differ between males and females, and young patients (21–30 years) showed greater improvement in diarrheal symptoms than did old patients (> 61 years). Although this report is based on the re-evaluation of old data that had been preserved by our company, the effectiveness and range of symptoms that were treatable with wood creosote has likely remained unchanged. To the best of our knowledge, this is the first public report on the clinical effectiveness of wood creosote capsules for the treatment of a wide range of diarrheal symptoms.

Keywords

diarrhea; wood creosote; Seirogan; retrospective study; capsule

Subject

Medicine and Pharmacology, Gastroenterology and Hepatology

Comments (1)

Comment 1
Received: 6 November 2019
Commenter: Masafumi Ito
Commenter's Conflict of Interests: Author
Comment: 2
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.